All In Biotech

NDA 210563 · Pharmacyclics LLC

Imbruvica

Ibrutinib · Oral · Kinase Inhibitor

Accelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 16, 2018

Approved uses

10

Original approval plus efficacy supplements

Registered trials

381

49 Phase 3, 31 recruiting

FAERS reports

80,997

63,021 serious, 13,832 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 21, 2025.

IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ). 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1. 2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. 1. 3 Waldenström’s Macroglobulinemia IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 1. 4 Chronic Graft versus Host Disease IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.

Mechanism: Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 2023 Supplement 17 · Efficacy OrphanLetterLabel
  • Aug 24, 2022 Supplement 14 · Efficacy · priority review OrphanLabel
  • Aug 24, 2022 Supplement 12 · Efficacy · priority review OrphanLabel
  • Aug 24, 2022 Supplement 13 · Efficacy · priority review Orphan
  • Dec 18, 2020 Supplement 9 · Efficacy OrphanLetterLabel
  • Apr 21, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetter
  • Jan 25, 2019 Supplement 2 · Efficacy · priority review OrphanLabelLetter
  • Aug 24, 2018 Supplement 1 · Efficacy · priority review OrphanLabelLetter
  • Feb 16, 2018 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalOrphanLabelLetterReview
  • Feb 16, 2018 Original approval · Efficacy · priority review OrphanLabelReview
4 products under this application
  • IMBRUVICA · IBRUTINIB 560MG · TABLET, ORAL · Discontinued
  • IMBRUVICA · IBRUTINIB 280MG · TABLET, ORAL · Prescription
  • IMBRUVICA · IBRUTINIB 420MG · TABLET, ORAL · Prescription
  • IMBRUVICA · IBRUTINIB 140MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibrutinib" as an intervention, any sponsor and status, largest first.

All 381 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death8,652
  • off label use6,069
  • fatigue4,780
  • diarrhoea4,224
  • atrial fibrillation3,926
  • pneumonia3,291
  • contusion2,827
  • incorrect dose administered2,779
  • fall2,544
  • asthenia2,378
  • nausea2,331
  • arthralgia2,226

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20125
201364
20141,286
20154,210
20164,326
20175,376
20187,196
20198,568
202010,342
20217,680
202213,527
20238,225
20244,441
20253,593
20262,158

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imbruvica (Ibrutinib)

2024 spending

$2.27B

Beneficiaries

15,351

146,416 claims

Per beneficiary

$147,629

$478.65 per unit

View as table
YearSpending
2020$2,962,909,304
2021$3,150,225,810
2022$2,853,910,970
2023$2,371,893,292
2024$2,266,252,032

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 459 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.